Clinical trials: Schizophrenia Spectrum Disorder
Psychotic Disorder
Peer Support for Exercise in Older Veterans With Psychotic Disorders
Older adults with psychotic disorders experience a dual set of challenges: those related to serious mental illness, and those related to aging.
- Trial name
- NCT02958007
- Testing
- Peer Education on Exercise for Recovery, Enhanced supervised fitness training
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- VA Office of Research and Development
Schizophrenia
Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia
This will be a multicenter, randomized, double-blind, placebo-controlled study designed to assess the tolerability, safety, and efficacy of OPC-34712 (0.25 to 6.0 mg) for the treatment of adult subjects hospitalized with an acute…
- Trial name
- STEP 203 (NCT00905307)
- Testing
- OPC-34712, Aripiprazole
- Where
- 73 sites in United States, Bulgaria and 10 more
- Volunteers
- 459 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Diabetes, Obesity
Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications
This program aims to help Veterans who take antipsychotic medications lose weight. The investigators use a program based on the American Diabetes Association's "Diabetes Prevention Program," and the investigators have modified it…
- Conditions
- Diabetes, Obesity, Weight Gain
- Trial name
- MAMAO (NCT00344500)
- Testing
- Behavioral Weight Loss Program
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- VA Office of Research and Development
Schizophrenia
Randomized Controlled Trial (RCT) of a Motivational Decision Support System
In this study we will definitively test the decision support system in a randomized controlled trial (RCT) among smokers with severe mental illness (SMI) psychotic disorders. The Specific Aims of the study are: 1.
- Trial name
- RCTEDSS (NCT02086162)
- Testing
- Web-based motivational decision support system, NCI Education
- Where
- 3 sites in United States
- Volunteers
- 184 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia and Disorders With Psychotic Features, Tobacco Use Disorder
Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia
There is a high prevalence of smoking among people with schizophrenia, and there are few smoking treatment programs for these smokers.
- Trial name
- NCT00136760
- Testing
- Bupropion, non-contingent reinforcement plus bupropion
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Brown University
Schizophrenia
A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia
A study to evaluate the efficacy and safety of an experimental drug (SEP-363856) in acutely psychotic adults with schizophrenia
- Trial name
- NCT02969382
- Testing
- SEP-363856
- Where
- 33 sites in United States, Hungary and 3 more
- Volunteers
- 245 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Insulin Resistance
Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia
This study will evaluate the effects of combination treatment with aripiprazole and clozapine on insulin resistance, blood fat levels, and weight gain in people diagnosed with schizophrenia.
- Trial name
- NCT00345033
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia
Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia
The purpose of this study is to determine if flexibly-dosed ziprasidone is safe and effective for the treatment of adolescents (ages 13-17) with schizophrenia
- Trial name
- NCT00257192
- Testing
- Ziprasidone oral capsules
- Where
- 92 sites in United States, Colombia and 7 more
- Volunteers
- 284 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia, Dual Diagnosis
Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?
In this translational research proposal, based on our formulation, we seek to confirm and expand upon data obtained in our pilot study suggesting that cannabis and the cannabinoid agonist dronabinol, given in low dose to patients…
- Conditions
- Schizophrenia, Dual Diagnosis, Psychotic Disorder, Cannabis Use Disorder
- Trial name
- NCT01964404
- Testing
- Marijuana, Dronabinol
- Where
- 2 sites in United States
- Volunteers
- 263 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia, Dual Diagnosis
Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual
Many individuals with schizophrenia also suffer from marijuana addiction. Clozapine, an atypical antipsychotic medication, may prove useful at preventing drug relapse in schizophrenic individuals who are seeking treatment for…
- Conditions
- Schizophrenia, Dual Diagnosis, Schizoaffective Disorder, Psychotic Disorder
- Trial name
- NCT00498550
- Testing
- Clozapine, Treatment as usual
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Psychosis, Schizophrenia
A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis
Many patients with schizophrenia and schizoaffective disorder have symptoms that persist, including hallucinations or delusions, despite adequate pharmacotherapy with antipsychotic drug.
- Conditions
- Psychosis, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT00591318
- Testing
- ceftriaxone, Normal Saline
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Research Foundation for Mental Hygiene, Inc.
Schizophrenia, Cognitive Effect on Schizophrenic Patients
Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia
This is a randomized, double-blind, active-controlled, 6 month study designed to evaluate the cognitive effects of treatment with CYP-1020 compared to risperidone.
- Trial name
- CLARITY (NCT01363349)
- Testing
- CYP-1020, Risperidone
- Where
- 39 sites in India, Moldova and 1 more
- Volunteers
- 269 people
- Sponsor
- BioLineRx, Ltd.
Mental Disorders, Severe, Schizophrenia and Related Disorders
A Trial of "Opening Doors to Recovery" for Persons With Serious Mental Illnesses
Insufficient community-based support after inpatient discharge for persons with serious mental illnesses (SMI) may lead to re-hospitalization, excessive criminal justice involvement, homelessness, and an inability to embrace…
- Conditions
- Mental Disorders, Severe, Schizophrenia and Related Disorders, Bipolar Disorder, Depressive Disorder
- Trial name
- ODR (NCT04612777)
- Testing
- Opening Doors to Recovery, Case Management, Intensive Case Management
- Volunteers
- 240 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia
A Study of Olanzapine in Patients With Schizophrenia
The primary objectives of the study is to confirm if the efficacy of intramuscular injection (IM) olanzapine 10 milligrams (mg) in patients with an exacerbation of schizophrenia with acute psychotic agitation is greater than…
- Trial name
- NCT00970281
- Testing
- Rapid-Acting Intramuscular Olanzapine
- Where
- 11 sites in Japan
- Volunteers
- 91 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
A Study Evaluating the of OPC-34712 in Subjects With Normal Hepatic Function and Hepatically Impaired Subjects
The purpose of this study is to evaluate how much of the investigational product gets into the blood stream and how long the body takes to get rid of it when given to subjects with a range of liver impairment compared to subjects…
- Trial name
- NCT01299454
- Testing
- OPC-34712
- Where
- 3 sites in United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Obese, Cigarette-smoking
Naltrexone and Bupropion Combination on Obese,Smoking Patients With Schizophrenia
The purpose of this research is to observe the efficacy of Naltrexone and Bupropion combination on weight loss and smoking cessation from baseline to week 24 compare to placebo.
- Conditions
- Obese, Cigarette-smoking, Schizophrenia
- Trial name
- NCT02736474
- Testing
- Naltrexone, Bupropion
- Volunteers
- 22 people
- Sponsor
- Shanghai Mental Health Center
Adolescent Schizophrenia, Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features
Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.
This is an open-label study consisting of a screening period, a conversion/titration phase (Phase 1), an open-label treatment phase (Phase 2), and a follow-up period.
- Trial name
- ATTAIN 267 (NCT01122927)
- Testing
- Aripiprazole
- Where
- 101 sites in United States, Bulgaria and 11 more
- Volunteers
- 524 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
L-arginine in Treatment as Usual in Schizophrenia
STUDY OBJECTIVES: To determine whether the addition of L-arginine to treatment as usual (TAU) in schizophrenia further improves and enhances therapeutic efficacy (positive, negative and depressive symptoms) and effectiveness of…
- Trial name
- NCT00718510
- Testing
- L-Arginine
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- University of Alberta
Schizophrenia, Schizophrenia Schizoaffective
Focused Ultrasound Modulation of the Globus Pallidus Interna in Schizophrenia
This is a single-site, phase 2, sham-controlled random-order cross-over pilot trial of PLIFUS targeting the right GPi in individuals with schizophrenia.
- Trial name
- NCT05643196
- Testing
- PLIFUS, MRI
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- NYU Langone Health
Tobacco Use, Tobacco Smoking
Persistence Targeted Smoking Cessation in Serious Mental Illness (SMI)
Due to the pandemic, this study was modified from a randomized clinical trial to test the feasibility, initial efficacy, and mechanisms of action of our PTSC-S intervention to a feasibility and acceptability test of our…
- Conditions
- Tobacco Use, Tobacco Smoking, Tobacco Use Cessation, Tobacco Use Disorder
- Trial name
- PTSC-S (NCT03873337)
- Testing
- Persistence Targeted Smoking Cessation in SMI (PTSC-S), Nicotine patch
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Rutgers, The State University of New Jersey